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Background: The majority of prosthetic heart valves are bioprostheses. Over time, bioprosthetic valves will predictably fail. Reoperation is 
associated with significant morbidity and mortality. Transcatheter heart valve (THV) implantation within a failed prosthesis may offer an effective and 
less invasive alternative.
Methods: “Valve-in-valve” (VIV) procedures were performed in patients with failed surgical and transcatheter aortic, mitral, pulmonary and 
tricuspid bioprosthetic valves at 4 centers. We describe this initial multicentre VIV experience using the Edwards Balloon Expandable Valve.
Results: In-vitro and in-vivo studies demonstrated the feasibility of THV implantation within surgical bioprostheses. Transcatheter VIV implantation 
was performed in 29 patients with failed bioprostheses (aortic n = 15, mitral n = 7, pulmonary n = 6, tricuspid n = 1) and prohibitive risk for 
conventional surgery (mean Society of Thoracic Surgery score 10.8 ±5.2, mean logistic EuroSCORE 24% ±14%). Implantation was successful in 
all patients with immediate restoration of satisfactory valve function. No patient had more than mild valvular or paravalvular regurgitation post 
implantation. There was no peri-procedural mortality. Thirty day mortality was 10.3%. At a median follow up of 120 days (inter-quartile range 37-260 
days), 86.2% of patients remain alive with satisfactory valve function. New York Heart Association functional class improved from a mean of 3.0 ± 
1.0 pre-procedure to a mean of 1.3 ± 0.7 at last follow-up (p<0.05).
Conclusions: Transcatheter VIV implantation is a reproducible approach for the management of failed bioprosthetic valves regardless of valve 
position. Optimal valve designs, implantation methods, and patient selection as well as long term durability remain to be determined prior to broad 
application.
